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determinants in regard to Enterobacteriaceae remains to be
determined. For Aeromonas spp. to act as a reservoir of qnr
genes, they must be capable of acquiring these determinants
from their progenitors [13] and of transferring this genetic
information to Enterobacteriaceae. Because Aeromonas are
ubiquitous in a wide range of environments, they might act
as important vectors for the transfer of plasmid-mediated
quinolone resistance [14].
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Abstract
Three isolates of Mycoplasma amphoriforme, a new Mycoplasma
species rarely described to date, were obtained from respiratory
tract specimens from two children and one adult with respira-
tory tract infections. Molecular methods were required to dis-
tinguish them from Mycoplasma pneumoniae. MICs of macrolides,
tetracyclines and ﬂuoroquinolones were identical to those for
M. pneumoniae, except for that of ciproﬂoxacin, which was
slightly more potent against M. amphoriforme. M. amphoriforme
could possibly have been involved in one case of severe respira-
tory infection with sepsis, but further studies are needed to
specify its role as a potential respiratory tract pathogen.
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Mycoplasma amphoriforme is a novel human Mycoplasma spe-
cies belonging to the phylogenetic group Pneumoniae [1].
Only 12 isolates have been reported, mainly from respiratory
tract specimens of patients with immunological disorders and
productive cough [2,3]. The mode of acquisition and the
pathogenic role of this species have not yet been established.
However, this organism is unlikely to be a common com-
mensal of the upper respiratory tract, as it has not been
detected in healthy persons or asymptomatic patients with
primary antibody deﬁciency [2]. Two difﬁculties could be
encountered in the diagnosis and treatment of this species.
First, M. amphoriforme may be easily confused with Myco-
plasma pneumoniae, the main respiratory tract pathogenic
mycoplasma species [1]. Second, it has been suggested that
this Mycoplasma species could be resistant to antibiotics that
are generally active against mycoplasmas [2]. We report the
detection and the susceptibility testing of three M. amphori-
forme clinical strains, isolated in France and in Tunisia.
A bronchoalveolar lavage sample and two throat swabs
were grown in Hayﬂick modiﬁed broth medium supple-
mented with glucose [4]. Broths with a colour change were
plated on Hayﬂick agar medium, and the DNA was extracted
from yellow broths using the MagNA Pure extraction system
(Roche, France). A real-time PCR targeting the M. pneumoniae
P1 adhesin gene was performed on DNA extracts as previ-
ously described [5]. DNA extracts were ampliﬁed with prim-
ers GPO1 and MGSO [6], targeting a conserved fragment of
the Mycoplasma 16S rRNA genes, and PCR products were
sequenced. Finally, DNA extracts were ampliﬁed with prim-
ers amph-F and amph-R, speciﬁc to the M. amphoriforme 16S
rRNA, as previously described [1]. MICs of macrolides and
related antibiotics, tetracyclines and ﬂuoroquinolones were
determined for the three clinical isolates by a broth dilution
method [4].
The three respiratory tract specimens led to a colour
change of the broth medium from red to yellow, after 15–20
days, indicating acidiﬁcation and bacterial growth. Plated on
agar medium, two of the three broths led to bubble-shaped
colonies resembling typical M. pneumoniae colonies. However,
the M. pneumoniae-speciﬁc real-time PCR remained negative
on all broths. Ampliﬁcation and sequencing of a 16S rRNA
gene fragment led to approximately 550-bp sequences present-
ing identities ranging from 98.7% to 99.7% with the 16S rRNA
gene from theM. amphoriformeA39 reference strain. Moreover,
a 550-bp ampliﬁcation product was obtained with the PCR
targeting the M. amphoriforme 16S rRNA gene [1]. Thus, the
identiﬁcation of three M. amphoriforme clinical isolates, namely
Ma3663, Ma4526 and G75, was conﬁrmed.
The Ma3663 isolate was cultured from a throat swab of a
previously healthy 35-year-old adult hospitalized in 2004 in
an intensive-care unit of the Bordeaux University Hospital
(France) for undocumented severe sepsis with a cutaneous
rash and a bilateral interstitial syndrome on the chest
radiograph. Except for M. amphoriforme, no other bacterial
or viral agent was found in his respiratory or blood speci-
mens. The Ma4526 isolate, as well as 4 · 106 CFU/mL
Haemophilus inﬂuenzae, were cultured from the bronchoalve-
olar lavage ﬂuid of a French 2-year-old girl hospitalized in
2007 at the same hospital for an exacerbation of cystic ﬁbro-
sis. The G75 strain and commensal oral bacteria were iso-
lated from a throat swab of a Tunisian 2-year-old boy with a
history of b-thalassaemia major, consulting in 2006 for an
undocumented productive cough with fever in the Bone
Marrow Transplant Centre of Tunis (Tunisia). None of the
three patients had received any antimycoplasmal antibiotic
treatment before or during the course of their infectious
syndrome. Moreover, M. pneumoniae serology ﬁndings
remained negative for all patients.
MICs for the three isolates are presented in Table 1, in
comparison with those for the M. pneumoniae M129 suscep-
tible reference strain. The three isolates were susceptible to
antibiotics usually active against mycoplasmas. MICs of mac-
rolides and related antibiotics, tetracyclines and ﬂuoroquinol-
ones were about the same as those for M. pneumoniae,
except for that of ciproﬂoxacin, which was more potent
against M. amphoriforme, with MICs four times lower than
TABLE 1. MICs (mg/L) of macrolides and related antibiotics, tetracyclines and ﬂuoroquinolones for three Mycoplasma amphor-
iforme clinical isolates in comparison with those obtained for the Mycoplasma pneumoniae M129 susceptible reference strain
Mycoplasmal strains
MIC
ERY AZM JOS CLI PRI TEL TET DOX CIP LEV MOX
M. amphoriforme
Ma3663 0.03 0.001 0.008 0.2 0.06 0.001 0.12 0.12 0.25 0.25 0.06
Ma 4526 0.015 0.001 0.008 0.5 0.06 0.002 0.12 0.12 0.25 0.25 0.03
G75 0.015 0.001 0.008 0.5 0.12 0.002 0.12 0.12 0.25 0.12 0.06
M. pneumoniae
M129 0.015 0.001 0.015 0.5 0.12 0.001 0.25 0.12 1 0.5 0.06
ERY, erythromycin A; AZM, azithromycin; JOS, josamycin; CLI, clindamycin; PRI, pristinamycin; TEL, telithromycin; TET, tetracycline; DOX, doxycycline; CIP, ciproﬂoxacin;
LEV, levoﬂoxacin; MOX, moxiﬂoxacin.
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that of M. pneumoniae (Table 1). The ciproﬂoxacin MICs of
0.25 mg/L for these M. amphoriforme clinical isolates con-
trasted with the ciproﬂoxacin MIC of 1.5 mg/L obtained for
the M. amphoriforme reference strain A39 with an agar dilu-
tion method [2]. Unfortunately, this strain was not available
for this difference to be checked.
As previously suggested [1], M. amphoriforme could be
easily missed and confused with M. pneumoniae by culture,
as both of them hydrolyse glucose and lack the characteris-
tic ‘fried egg’ appearance of many mycoplasmas. In conse-
quence, molecular methods were required to distinguish
them.
M. amphoriforme was previously described as an opportun-
ist that was probably pathogenic in immunodeﬁcient patients
and did not belong to the commensal respiratory ﬂora [1,3].
Its pathogenic role was reinforced by the study of its deter-
gent-insoluble structure, which was similar to the electron-
dense core of the M. pneumoniae attachment organelle
required for virulence [7]. In our study, two children had an
underlying immunodepressive disease. However, the clinical
signiﬁcance of the detection of M. amphoriforme was uncer-
tain in both cases, as the microbiological information was
incomplete, and both children recovered without receiving
an antibiotic active against mycoplasmas. In contrast, the
adult with severe sepsis was a previously healthy person
without any immunological disorder or antecedents. As no
other bacterial or viral agent was found, M. amphoriforme
could possibly be considered to be involved in his severe
infectious syndrome, which resulted in a 2-month stay in an
intensive-care unit. Unfortunately, the detection of the myco-
plasmal origin was too late for antibiotic treatment active
against mycoplasmas to be started.
In conclusion, M. amphoriforme was isolated in respiratory
specimens from three patients with respiratory tract infec-
tions, but molecular methods were required to distinguish it
from M. pneumoniae. This species was susceptible to antibiot-
ics that are generally active against mycoplasmas, and was
slightly more susceptible to ciproﬂoxacin than M. pneumoniae.
In this study, M. amphoriforme could possibly be involved in
one case of severe respiratory infection with sepsis. More-
over, to add to the epidemiological knowledge of this species
and to specify its role as a potential respiratory pathogen,
further studies on its detection in respiratory tract speci-
mens with molecular methods are needed.
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Abstract
We report the ﬁrst international spread and dissemination of
ST93-SCCmecIV (Queensland clone) methicillin-resistant Staphy-
lococcus aureus (MRSA), previously identiﬁed in communities and
hospitals in Australia. Ten highly genetically related MRSA iso-
lates and one methicillin-susceptible S. aureus (MSSA) isolate
were identiﬁed in England between 2005 and June 2008. The
demography and clinical features were typical for community-
associated-MRSA. One female with MRSA infection died from
necrotizing pneumonia. Travel between Australia and the UK,
and some onward transmission, suggested that both importation
and clonal dissemination of this strain had occurred, albeit to a
small extent. Nosocomial transmission was not detected, but we
remain vigilant for further importations and/or spread.
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